ELUTIA INC. (ELUT) - Dilution Analysis

10-Q filing | 43.0M shares outstanding

10-K filing | 41.4M shares outstanding

10-Q filing | 42.4M shares outstanding

10-Q filing | 4.3M shares outstanding

10-Q filing | 4.3M shares outstanding

8-K filing: Elutia Inc. issued 1,105,528 shares of Class A Common Stock to Ligand Pharmaceuticals to satisfy $2.2 million in royalty obligations and issued 50,000 shares of Class A Common Stock to lenders in consideration for an amendment to a credit agreement. ($2.2M proceeds)

S-3 filing: Elutia Inc. is offering up to $100,000,000 in the aggregate of Class A common stock, Class B common stock, preferred stock, and debt securities from time to time in one or more offerings for general corporate purposes.

10-K filing | 4.3M shares outstanding

8-K filing: Elutia Inc. completed a registered direct offering on February 4, 2025, selling 5,520,000 shares of Class A common stock at $2.50 per share and prefunded warrants to purchase up to 480,000 shares of Class A common stock at $2.499 per warrant, raising gross proceeds of approximately $15.0 million before deducting fees and expenses. ($15.0M proceeds)

10-Q filing | 4.3M shares outstanding

10-Q filing | 4.3M shares outstanding

8-K filing: Elutia Inc. completed a registered direct offering of 3,175,000 shares of Class A common stock and prefunded warrants to purchase up to 725,000 shares of Class A Common Stock for gross proceeds of approximately $13.26 million before deducting fees and expenses. ($13.26M proceeds)

10-Q filing | 4.3M shares outstanding

10-K filing | 4.3M shares outstanding

S-3 filing: Elutia Inc. is offering 18,577,644 shares of Class A common stock by selling securityholders via a shelf registration statement.

10-Q filing | 4.3M shares outstanding

8-K filing: Elutia Inc. sold 6,852,811 common units and 503,058 prefunded units at $1.4275 and $1.4265 per unit, respectively, for gross proceeds of $10.5 million. ($31.5M proceeds)

10-Q filing | 4.3M shares outstanding

10-Q filing | 11.9M shares outstanding

10-K filing | 11.8M shares outstanding

8-K filing: Aziyo Biologics, Inc. completed a public offering of 2,350,000 shares of Class A common stock at $4.75 per share, expecting net proceeds of approximately $9.84 million. ($11.16M proceeds)

10-Q filing | 4.3M shares outstanding

S-3 filing: Aziyo Biologics, Inc. may offer and sell up to $50,000,000 in the aggregate of Class A Common Stock, Class B Common Stock, Preferred Stock, Debt Securities, Warrants, and Units from time to time in one or more offerings.

10-Q filing | 4.3M shares outstanding

8-K filing: Aziyo Biologics, Inc. entered into a Credit Agreement with SWK Funding LLC on August 10, 2022, providing for a $21.0 million term loan, an additional $4.0 million term loan tranche, and an $8.0 million asset-based revolving facility; and issued a warrant to SWK Funding LLC to purchase up to 187,969 shares of Class A common stock at $6.65 per share, subject to adjustments for stock splits and dividends.

10-Q filing | 4.3M shares outstanding

10-K filing | 9.2M shares outstanding

8-K filing: Aziyo Biologics, Inc. entered into amendments to its credit and security agreements and sold shares of Class A and Class B common stock to investors, resulting in gross proceeds of approximately $14.0 million. ($28.0M proceeds)

S-3 filing: This S-3 filing relates to the offering of 3,301,881 shares of Class A common stock by selling securityholders. 2,122,637 shares are presently issued and outstanding and 1,179,244 shares are issuable upon conversion of presently issued and outstanding shares of Class B common stock. The selling securityholders may offer and sell these shares from time to time.

8-K filing: Aziyo Biologics, Inc. sold 2,122,637 shares of Class A common stock and 1,179,244 shares of Class B common stock at $4.24 per share for gross proceeds of $14.0 million in a completed offering. ($14.0M proceeds)

10-Q filing | 3.1M shares outstanding

10-Q filing | 3.1M shares outstanding

10-Q filing | 7.1M shares outstanding

10-K filing | 7.1M shares outstanding

10-Q filing | 7.1M shares outstanding

8-K filing: Aziyo Biologics, Inc. filed a restated certificate of incorporation in connection with the closing of its IPO, authorizing 200,000,000 shares of Class A common stock and 20,000,000 shares of Class B common stock and also closed an IPO issuing 2,205,882 shares of Class A common stock and 735,294 shares of Class B common stock at $17.00 per share. ($50.0M proceeds)

S-1/A filing: This is an S-1/A filing for an offering of Class A common stock underwritten by Piper Sandler, Cowen, Cantor, and Truist Securities.

S-1 filing: This is an S-1 filing for an initial public offering of Class A common stock underwritten by Piper Sandler, Cowen, Cantor, and Truist Securities.